Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 1/2 3Phase 3 1Phase 2/3 1Phase 1 1

Status

Terminated 2Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Other hematologic neoplasm 1

Conditions

Recurrence 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Non-Hodgkin 1Lymphoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1

Interventions

Cyclophosphamide 143pembrolizumab 127Nivolumab 116Carboplatin 99Dexamethasone 93Rituximab 91Paclitaxel 87Gemcitabine 85Lenalidomide 75Cytarabine 74Radiotherapy 73Cisplatin 70Bevacizumab 64Etoposide 62fludarabine phosphate 58fludarabine 56Ipilimumab 55Docetaxel 54Bortezomib 54Prednisone 49Doxorubicin 48Temozolomide 47Everolimus 46Erlotinib Hydrochloride 46Fluorouracil 44Azacitidine 44Capecitabine 43Calcium Dobesilate 43Filgrastim 42Melphalan 41

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Has results × tafasitamab × Clear all
NCT04809467 2026-02-04

topMIND

Incyte Corporation

Phase 1/2 Terminated
54 enrolled 23 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Non-Hodgkin, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT05222555 2026-01-16

MINDway

Incyte Corporation

Phase 1/2 Active not recruiting
53 enrolled 14 charts
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT05626322 2025-09-05

Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Pfizer

Phase 1/2 Terminated
6 enrolled 17 charts
Lymphoid

Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡